Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Infection of domestic and wild fowl and other birds with influenza A virus. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic poultry.
Estimated prevalence: Unknown (Unknown prevalence).
7 clinical trials registered, 3 recruiting. Interventions under study include other interventions and biologic therapy. Pipeline includes 1 PHASE4, 2 PHASE3, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06850298](https://clinicaltrials.gov/study/NCT06850298) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:03 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
H5N1 Milk Detection Study
NA |
Emory University |
RECRUITING |
[NCT07240558](https://clinicaltrials.gov/study/NCT07240558) | Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) | PHASE3 | University Health Network, Toronto | RECRUITING |
[NCT07275060](https://clinicaltrials.gov/study/NCT07275060) | Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart | PHASE4 | Canadian Immunization Research Network | ACTIVE_NOT_RECRUITING |
[NCT06842173](https://clinicaltrials.gov/study/NCT06842173) | Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults | PHASE1 | Butantan Institute | RECRUITING |
[NCT07019883](https://clinicaltrials.gov/study/NCT07019883) | A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults | PHASE1 | National Institute of Allergy and Infectious Diseases (NIAID) | UNKNOWN |
339 publications have been identified in PubMed for avian influenza. Kisho has analyzed 54 by research type. Research spans Review / Meta-Analysis (37%), Epidemiology / Natural History (30%), and Other (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 20 | 37% |
Disease patterns and progression | 16 | 30% |
Other research | 8 | 15% |
Laboratory research | 6 | 11% |
Patient case studies | 3 | 6% |
New treatment approaches | 1 | 2% |
Panagiotopoulos AP (2026). [PMID: 41864359](https://pubmed.ncbi.nlm.nih.gov/41864359/). *Int J Antimicrob Agents*. [Review / Meta-Analysis]
Ding K (2026). [PMID: 42107281](https://pubmed.ncbi.nlm.nih.gov/42107281/). *Virology*. [Review / Meta-Analysis]
Hernández M (2026). [PMID: 41505842](https://pubmed.ncbi.nlm.nih.gov/41505842/). *Med Clin (Barc)*. [Other]
Farrell ML (2026). [PMID: 41739543](https://pubmed.ncbi.nlm.nih.gov/41739543/). *J Gen Virol*. [Basic Science / Preclinical]
Panzarin V (2025). [PMID: 40618304](https://pubmed.ncbi.nlm.nih.gov/40618304/). *Food Environ Virol*. [Basic Science / Preclinical]
European Food Safety Authority (2025). [PMID: 41425765](https://pubmed.ncbi.nlm.nih.gov/41425765/). *EFSA J*. [Epidemiology / Natural History]
Zhao Z (2025). [PMID: 41258791](https://pubmed.ncbi.nlm.nih.gov/41258791/). *Virulence*. [Basic Science / Preclinical]
Diaby M (2025). [PMID: 40146750](https://pubmed.ncbi.nlm.nih.gov/40146750/). *PLoS One*. [Epidemiology / Natural History]
European Food Safety Authority, European Centre for Disease Prevention and Control (2025). [PMID: 39802641](https://pubmed.ncbi.nlm.nih.gov/39802641/). *EFSA J*. [Epidemiology / Natural History]
European Food Safety Authority (EFSA) (2025). [PMID: 41404625](https://pubmed.ncbi.nlm.nih.gov/41404625/). *EFSA J*. [Epidemiology / Natural History]
AI-curated news mentioning avian influenza
Updated Sep 1, 2026
GSK is set to launch a Phase 3 trial for its mRNA-based flu vaccine in September, following promising mid-stage results showing enhanced immune responses in both younger and older adults. This move comes on the heels of the FDA's approval of Moderna's mRNA flu vaccine, indicating a growing interest in mRNA technology for influenza.
CDC provides updated information on the relationship between respiratory infections like flu, COVID, and RSV with asthma. This guidance aims to inform public health strategies and patient management.
Moderna's mRNA flu vaccine faces challenges despite FDA approval, including strain selection timing and skepticism around mRNA technology. These factors could hinder its market impact as a potential blockbuster.
Moderna's flu vaccine, mFLUVISA, has received FDA approval following a previous refusal-to-file letter. The advisory committee unanimously supported its approval, marking a significant milestone for the company.
A case report details severe pneumonia and acute respiratory distress syndrome in a young female caused by avian influenza A (H10N3). This highlights the potential severity of H10N3 infections and the need for further research.